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Chronic obstructive pulmonary disease (COPD) is a widespread respiratory disorder, usually characterized by
progressive and poorly reversible airflow limitation. Inhaled long-acting bronchodilators, namely LABA (long-acting
β2-adrenergic agonists) and LAMA (long-acting muscarinic receptor antagonists) are the mainstay of COPD
treatment. Because the symptoms of many patients with COPD do not satisfactorily improve by using a single,
either LABA or LAMA bronchodilator, the synergism of action resulting from the combination of the different
bronchodilating mechanisms activated by LABA and LAMA, respectively, can significantly contribute to a better
disease control. Based on these clinical and pharmacological considerations, several LABA/LAMA fixed-dose
combinations have been developed and experimentally evaluated. Within such a context, the drug co-formulation
containing indacaterol and glycopyrronium is probably the LABA/LAMA association which has been most extensively
studied during the last few years.
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COPD is characterized by a barely reversible airflow
limitation, thus it is easily understandable that inhaled
bronchodilators such as LABA and LAMA are the main
pharmacological options in order to improve lung func-
tion, dyspnea, exercise tolerance and overall quality of
life, as well as to prevent disease exacerbations [1].
Moreover, current guidelines recommend the combined
use of LABA and LAMA when symptoms are not ad-
equately improved by a single bronchodilator [2]. The
rationale of using these two drug classes is based on
their ability to effectively interfere with the bronchocon-
strictive signaling network leading to the respiratory dys-
function underlying COPD. In particular, by means of
different mechanisms of action, LABA and LAMA can
counteract the increased bronchomotor tone, which in
COPD patients is mainly sustained by an excessive acti-
vation of cholinergic pathways. Therefore, LABA and* Correspondence: pelaia@unicz.it
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unless otherwise stated.LAMA act cooperatively by reciprocally potentiating their
bronchodilating effects [3]. These positive pharmaco-
logical interactions can be further amplified by the differ-
ent distribution patterns of receptor targets throughout
the bronchial tree. Indeed, bronchodilating β2-adrenergic
receptors (β2-ARs) are located along all the respiratory
system, but their density progressively increases from the
proximal, larger airways towards the distal, smaller ones.
Vagal cholinergic innervation is mostly distributed within
the central airways, where bronchoconstrictive muscarinic
receptors are present in higher numbers; however, extra-
neuronal acetylcholine (ACh) mainly activates muscarinic
receptors placed in peripheral airways [4]. Among LABA/
LAMA combinations, a remarkable amount of pharmaco-
logical and clinical information has been obtained by
evaluating the effects of the fixed-dose co-formulation of
indacaterol and glycopyrronium, known as QVA149 [5].
Indacaterol is a LABA used once daily, as it provides a
prolonged bronchodilation, lasting at least 24 hours [6,7].
Glycopyrronium (NVA237) is a recently developed LAMA
that, similarly to indacaterol, induces a persistent, 24
hour-long bronchodilation, thus being also suitable for
once daily administration [8,9]. Therefore, by acting viahis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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indacaterol and glycopyrronium can exert synergistic ef-
fects, thereby optimizing and maximizing bronchodila-
tion in those COPD patients whose needs are not
adequately met by a monotherapy performed with a sin-
gle bronchodilator.
The aim of this review article is firstly to outline the
mechanisms of action of QVA149, and then discuss its
clinical and functional effects, as well as the safety and
tolerability profile.
Review
Basic mechanisms of action
All β2-adrenergic receptor (β2-AR) agonists, also including
indacaterol, relax airway smooth muscle (ASM) regardless
of the nature and multitude of bronchoconstrictive stim-
uli, thus acting as functional antagonists of bronchocon-
striction. In particular, these drugs activate β2-ARs, which
are coupled to the stimulatory G protein (Gs) that is, in
turn, responsible for the stimulation of adenylyl cyclase
(AC) and the subsequent increase in the concentration of
intracellular second messenger cyclic adenosine 3’5’-
monophosphate (cAMP) (Figure 1) [10]. The latter acti-
vates cAMP-dependent protein kinase A (PKA), which
phosphorylates several targets within the cell, thereby
leading to inhibition of Ca2+-dependent ASM contraction
[11]. Indacaterol is a powerful β2-adrenergic agonist, being
able to induce a very fast and prolonged bronchodilation,
which lasts for approximately 24 hours [12]. This drug has
an intense intrinsic activity at the level of β2-ARs, and its
bronchodilating action does not elicit significant tachy-
phylaxis. Unlike salmeterol, indacaterol does not alter theFigure 1 Dual bronchodilation induced by the fixed-dose co-formulatio
relaxation of airway smooth muscle via a prolonged activation of β2-adrenerg
β and γ subunits) to adenylyl cyclase, which catalyzes the synthesis of the intr
indacaterol is greatly enhanced by glycopyrronium, which provides a prolonged
dissociates very slowly from these receptors, whereas it quickly detaches fro
bronchoconstriction via inactivation of adenylyl cyclase mediated by an inh
primarily responsible for pre-junctional inhibition of acetylcholine release.fluidity of cell membrane, and its long-lasting bronchodi-
lating effect is due to a high affinity of the lipophilic tail of
the molecule for the so-called “lipid rafts” [13]. These
consist of micro-domains rich in cholesterol and sphingo-
lipids, that, within the cell membrane, function as aggre-
gation sites for β2-ARs, thus also facilitating their
connection with the signaling pathway including Gs and
AC. The rapid onset of the bronchodilating action of inda-
caterol depends on its hydrophilic head, which interacts
with the β2-AR hydrophilic pocket surrounded by the
seven hydrophobic transmembrane domains of this G
protein-coupled receptor.
The bronchoconstrictive effect of ACh can be inhib-
ited by inhaled anticholinergic drugs, which act through
a competitive antagonism of muscarinic receptors. Gly-
copyrronium bromide is a powerful once-daily inhaled
anticholinergic agent, characterized by a high kinetic
selectivity for M3 versus M2 muscarinic receptors
(Figure 1) [14,15]. Therefore, glycopyrronium operates
via a prolonged blockade of M3 receptors, whereas this
drug rapidly dissociates from M2 receptors. With regard
to airway muscarinic receptors, this kinetic pattern of gly-
copyrronium is very relevant, in that ACh-dependent
ASM contraction is mainly mediated by M3 receptors,
whilst M2 receptors are primarily responsible for prejunc-
tional inhibition of ACh release from postganglionic vagal
nerves [16,17]. Furthermore, cardiac M2 receptors modu-
late atrial pacemaker activity, atrio-ventricular conduction
and ventricular electro-mechanical coupling [18]. A per-
sistent blockade of M2 muscarinic receptors could thus at-
tenuate bronchodilation primarily due to M3 receptor
antagonism, as well as increase the risk of unwantedn of indacaterol/glycopyrronium. Indacaterol induces a long-lasting
ic receptors, coupled through a stimulatory G protein (consisting of αs,
acellular second messenger cAMP. The bronchodilation induced by
competitive blockade of M3 muscarinic receptors. Indeed, glycopyrronium
m M2 receptors. Although the latter may partially contribute to
ibitory G protein (consisting of αi, β and γ subunits), they are, however,
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rhythmias.Therefore, by largely preserving M2 receptor
functions, glycopyrronium maximizes bronchodilation
and is also characterized by a very good pattern of cardio-
vascular safety [8,9].
The remarkable bronchodilating action of glycopyrro-
nium is thus mainly mediated by a very effective preven-
tion of the activation of M3 receptors, coupled to the Gq
protein that, in turn, stimulates the β isoform of phos-
pholipase C (PLC-β), which cleaves phosphatidyl-inositol
4,5-bisphosphate (PIP2) into two intracellular second
messengers: inositol 1,4,5-trisphosphate (IP3) and 1,2
diacylglycerol (DAG) [19]. IP3 activates its receptor lo-
calized in the sarcoplasmic reticulum (SR), thereby re-
leasing into the cytosol calcium ions (Ca2+) which bind
to calmodulin, thus inducing the activation of myosin
light chain kinase (MLCK). MLCK phosphorylates my-
osin light chain (MLC), thereby promoting the subse-
quent actin-myosin interaction, which is responsible for
ASM contraction. The long-lasting bronchodilating ef-
fect of glycopyrronium is associated with a very fast on-
set of action, due to the rapid occupancy of muscarinic
receptors. Such an immediate blockade of ASM M3 re-
ceptors is thus responsible for a prompt decrease in
cytosolic Ca2+ levels, paralleled by a rapid inhibition of
bronchoconstriction elicited by cholinergic agents [15].
The advantageous bronchodilating pattern of glycopyr-
ronium explains its excellent therapeutic profile, emer-
ging from several clinical trials. In particular, the
GLOW1 and GLOW2 studies showed that glycopyrro-
nium provides a rapid and sustained FEV1 (forced expira-
tory volume in one second) increase, already detectable
within 5 minutes of administration [9,20].
In addition to their direct bronchodilating effects,
LABA and LAMA are also capable of indirectly affecting
bronchomotor tone by implementing, inside ASM, im-
portant cross-talks between cholinergic and adrenergic
pathways. Hence, by powerfully stimulating β2-ARs,
indacaterol can inactivate the signaling cascade under-
lying ACh-induced bronchoconstriction via an effective
inhibition of the activity of M3 muscarinic receptor-
coupled Gq protein. This mechanism is mediated by a
cAMP/PKA-dependent transcriptional stimulation of the
expression of regulator of G-protein signaling 2 (RGS2),
which specifically inhibits Gq activation [21]. On the
other hand, muscarinic receptor antagonists such as gly-
copyrronium can either restore or potentiate and amp-
lify the bronchodilating action of β2-adrenergic agonists
not only by inhibiting the IP3-dependent intracellular ef-
fects triggered by M3 receptor stimulation, but also by
preventing the deleterious effects on β2-AR function
elicited by the ACh-activated M3/Gq/PLC/DAG/PKC
signaling pathway. Indeed, by stimulating ASM M3 re-
ceptors, ACh is also able to induce DAG-mediatedactivation of protein kinase C (PKC) [19]. PKC can thus
phosphorylate specific serine residues located within the
third intracellular loop of β2-AR, as well as the α subunit
of Gs protein, thereby uncoupling these two key compo-
nents of the signal transduction cascade underlying the
bronchodilating action of β2-adrenergic agonists [22,23].
Moreover, PKC can also phosphorylate and activate
G-protein coupled receptor kinase 2 (GRK2), which in
turn promotes the phosphorylation of specific threonine
and serine residues located within the C-terminal cyto-
plasmic tail of β2-AR, thus further enhancing β2-AR/Gs
uncoupling as well as facilitating binding of β-arrestins to
the C-terminus of β2-AR, with subsequent intracellular re-
ceptor sequestration [24,25].
The above mentioned cooperation between indacaterol
and glycopyrronium, occurring within ASM at a post-
junctional level, can also extend to the pre-junctional
site, i.e. at the level of vagal postganglionic nerve end-
ings. Prejunctional inhibition of ACh release is indeed
mediated by indacaterol-dependent β2-AR activation, as
well as by stimulation of M2 muscarinic inhibitory re-
ceptors [3]. Indeed, the function of prejunctional M2 re-
ceptors is largely preserved by glycopyrronium, which
dissociates very rapidly from them, whereas this drug
blocks for a long time the postjunctional M3 muscarinic
receptors (Figure 1), mainly responsible for bronchocon-
striction and mucus hypersecretion.
Clinical and functional effects
On the basis of the above discussed pharmacological
concepts, several controlled trials have been carried out
to evaluate the potential benefits of QVA149 in COPD
treatment [5]. The positive results of such studies have
led to the recent approval of this drug co-formulation in
Europe, Canada and Japan [26-28]. All these trials have
been performed using the Breezhaler® dry powder
device, containing a capsule including 110 mcg of inda-
caterol and 50 mcg of glycopyrronium. The delivered
dose, leaving the inhaler at the level of its mouthpiece,
consists of 85 mcg of indacaterol and 43 mcg of glyco-
pyrronium, respectively.
The double-blind, randomized and placebo-controlled
trial called ENLIGHTEN was carried out for 52 weeks in
339 patients with moderate-to-severe COPD, who exhib-
ited post-bronchodilator FEV1 measurements ranging
from 30% to 80% of predicted values [29]. QVA149 signifi-
cantly improved lung function, thus steadily increasing
FEV1 throughout the whole study period. Furthermore,
QVA149 was remarkably more effective than placebo in
decreasing both respiratory symptoms and the use of as-
needed short-acting rescue bronchodilators [29]. The
main aim of the SPARK study, performed in 362 centers
located in 27 countries, was to evaluate the efficacy of
QVA149, by comparing it over 64 weeks to either
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of COPD exacerbations [30]. In particular, 2,224 patients
with severe or very severe COPD were enrolled, present-
ing a post-bronchodilator FEV1 less than 50% of pre-
dicted, who had experienced at least one exacerbation in
the year prior to enrollment. Therefore, following a
double-blind, randomized design, 741 subjects were
assigned to treatment with QVA149, 741 to monotherapy
with glycopyrronium (50 mcg daily through Breezhaler
device) and 742 to monotherapy with tiotropium (18
mcg daily via HandiHaler device). The results showed
that QVA149 was able to significantly reduce the overall
rate of all COPD exacerbations (mild, moderate and se-
vere), at rates of 15% and 14% when compared to glyco-
pyrronium and tiotropium, respectively [30]. Furthermore,
a recent meta-analysis demonstrated that QVA149 can
delay by 35% the onset of the next exacerbation [31]. With
respect to glycopyrronium and tiotropium, the SPARK
study also showed that QVA149 was able to induce a per-
sistently and significantly greater increase in trough FEV1.
Moreover, QVA149 was also more effective than either
glycopyrronium or tiotropium in improving the global
health status, as assessed by St. George’s Respiratory
Questionnaire (SGRQ).
In the SHINE study, 2,144 patients with moderate-to-
severe COPD (post-bronchodilator FEV1 range: from
30% to 80% of predicted values) were randomly divided
into five groups, each one receiving for 26 weeks, as
once daily administration, one of the following treat-
ments: 1) QVA149 (475 patients); 2) indacaterol 150
mcg (477 patients), 3) glycopyrronium 50 mcg (475 pa-
tients); 4) tiotropium 18 mcg (483 patients); 5) placebo
(234 patients) [32]. With the exception of the group of
patients undergoing treatment with tiotropium, who
used the dry powder inhaler “HandiHaler”, all the other
groups used Breezhaler as dry powder device. The ma-
jority of patients were male (75.4%), and had not experi-
enced exacerbations during the year prior to enrollment
(74.6%). Before starting the various treatments, there
were no significant spirometric differences among the
five groups. The results of the spirometries performed at
week 26 of treatment showed that QVA149 induced,
when compared to monotherapies with either indaca-
terol, glycopyrronium, tiotropium or placebo, significantly
greater increases in trough FEV1 and peak expiratory flow
(PEF) [32]. With respect to placebo, tiotropium and glyco-
pyrronium at week 12, as well as in comparison to tiotro-
pium and placebo at week 26, QVA149 induced a greater
improvement in dyspnea, assessed by transition dyspnea
index (TDI). At the end of the study the overall health sta-
tus, evaluated through the SGRQ score, resulted to be also
significantly improved in the group treated with QVA149,
when compared to the groups treated with either tiotro-
pium or placebo. Furthermore, a significant decrease inthe consumption of as needed short-acting bronchodila-
tors, used as rescue medications, was detected in the
group treated with QVA149, when compared to the other
four groups.
The aim of the multicenter, double-blind, randomized
ILLUMINATE trial, was to assess the effectiveness of
QVA149 in comparison to the fixed LABA/ICS (inhaled
corticosteroid) combination consisting of salmeterol 50
mcg plus fluticasone propionate 500 mcg (SFC), deliv-
ered twice daily via Diskus dry powder inhaler [33]. In
particular, this study lasted 26 weeks and included 523
current or ex-smokers with moderate to severe COPD
(age ≥ 40 years), who had no disease exacerbation during
the year prior to their enrollment. Airflow limitation was
characterized by a post-bronchodilator FEV1 ranging
from 40% to 80% of the predicted values. The results of
this study showed that QVA149 induced, when com-
pared to SFC, a significantly higher FEV1 increase,
already detectable during the first study day, as well as
at the 12th and 26th week [33]. QVA149 was significantly
more effective than SFC in decreasing the use of as
needed short-acting bronchodilators, as well as in im-
proving dyspnea, assessed by TDI. No significant differ-
ence was found between the two treatments with
regard to health status, assessed by SGRQ [33]. A lo-
gical extension of this study is the ongoing FLAME
trial, which is investigating the effects of QVA149,
compared with SFC, on COPD exacerbation rates [34].
LANTERN is a further ongoing study which is evaluat-
ing the efficacy of QVA149 versus SFC over 26 weeks,
in COPD patients from Argentina, Brazil, Chile, China
and Taiwan [35].
The BRIGHT study investigated the effects of QVA149
on exercise tolerance, lung volumes, and dynamic hyper-
inflation in patients with moderate-to-severe COPD over
3 weeks [36]. This trial showed that exercise endurance
time was significantly increased by QVA149 when com-
pared to placebo, with an improvement pattern similar
to that induced by tiotropium. Moreover, in comparison
to placebo and tiotropium, QVA149 elicited significantly
greater decreases in lung hyperinflation both at rest and
during exercise [36]. Of remarkable clinical relevance
are also the results of the BLAZE study, a multicentre,
blinded, double-dummy, crossover trial, which enrolled
247 patients with moderate-to-severe COPD who were
randomly assigned to receive once-daily QVA149, pla-
cebo or tiotropium [37]. Improvements in dyspnea were
assessed via the self-administered computerized (SAC)
version of TDI after 6 weeks. At this time, the SAC TDI
total score resulted significantly higher when patients
used QVA149, as compared with both placebo and tio-
tropium. Treatment with QVA149 was also associated,
when compared to either placebo or tiotropium, with a
significantly lower use of rescue medications [37].
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to the excellent medium- and long-term clinical and
functional effects induced by QVA149, the therapeutic
profile of this drug co-formulation is also characterized
by a very fast onset of bronchodilation, already detect-
able at 5 min post-dose on day one [32,33,37,38]. This
feature of QVA149 is very important in that it makes
possible to provide an immediate symptom relief, espe-
cially in the morning soon after awakening. Overall, the
efficacy of QVA149 is very similar to that achievable
with the concurrent administration of its monocompo-
nents indacaterol and glycopyrronium [39]. Indeed, the
BEACON trial, which enrolled 193 patients randomized
to receive either QVA149 or indacaterol plus glycopyrro-
nium as concurrent, independent inhalations, docu-
mented that both treatment groups experienced similar
FEV1 improvements, as well as analogous reductions in
symptom scores and rescue medication use [39].
Safety and tolerability profile
According to many studies, QVA149 is well tolerated
and is characterized by a favourable safety profile with
respect to its individual monocomponents [26]. A pooled
analysis of 6-month safety data extrapolated from SHINE,
ILLUMINATE, ENLIGHTEN and ARISE (a safety study
carried out in Japanese patients) trials, showed that the
proportion of subjects treated with QVA149 who experi-
enced cardio- and cerebro-vascular events was very simi-
lar to that detected in COPD patients treated with
tiotropium (1.8% and 1.7%, respectively), and lower than
that observed in patients receiving treatment with pla-
cebo (2.6%) [40]. The proportion of patients who re-
ported one or more cardio- and cerebro-vascular serious
adverse events in the QVA149 group was 0.6%, compar-
able to or slightly lower than those reported by patients
undergoing other active treatments [40]. Additionally, no
significant differences among QVA149 and the other
treatment groups were detected with regard to the inci-
dence of unwanted side effects in SPARK, BRIGHT and
BLAZE studies [30,36,37].
In general, once-daily dosing of QVA149 is well ac-
cepted by COPD patients [5]. Moreover, the combined
use of indacaterol and glycopyrronium is further favoured
by the inhalation device used. In fact, the dry powder in-
haler Breezhaler is characterized by a low airflow resist-
ance, that thus allows the activation of the device with an
affordable inspiratory effort [41]. This feature is very im-
portant because Breezhaler can thus be easily used even
by patients with the most severe forms of COPD, which of
course include the main candidates for the dual, LABA/
LAMA, combined therapy. In fact, the magnitude of the
peak inspiratory flow (PIF) decreases gradually as disease
severity increases. However, since Breezhaler can be acti-
vated by a relatively low inspiratory flow, its use ismarkedly suitable for almost all patients with COPD, also
including those characterized by the most severe degrees
of respiratory functional impairment. In addition, Breezhaler
has other remarkable advantages, especially related to
auditory, gustatory and visual perceptions, that make it
possible for the patient to be sure of having properly in-
haled drug medications. Indeed, the release of a drug fixed
dose by Breezhaler is associated with an audible hum in
the inhalation chamber, the sensation of a sweet taste due
to the presence of lactose, and the appreciation of powder
emptying due to the transparency of the capsule inserted
into the inhaler. All these features of Breezhaler, associated
with the advantage of once daily administration, guarantee
a high degree of compliance by COPD patients, with a
consequent considerable increase in the adherence to pre-
scribed inhaled therapy [42].Conclusions
Based on the above study results, it can thus be argued
that a dual bronchodilating treatment, performed through
the use of an inhaled pharmaceutical formulation capable
of simultaneously delivering indacaterol and glycopyrro-
nium, is characterized by a greater therapeutic effective-
ness when compared to monotherapies consisting of each
drug administered alone. Therefore, this experimental evi-
dence confirms the pharmacologic rationale underlying
the synergistic potentiation of the bronchodilating actions
exerted by different drugs such as LABA and LAMA,
which act via distinct mechanisms of action. Such an en-
hanced therapeutic efficacy can be achieved without in-
creasing the incidence of adverse events. This suggests
that the co-formulation of indacaterol and glycopyrronium
can be usefully utilized to optimize and maximize bron-
chodilation in many COPD patients, who do not experi-
ence an adequate airflow increase by using a single
bronchodilator. This results in greater improvements in
subjective symptoms, lung function and overall quality of
life. In addition, the enhancement of airway stabilization
and the long-term persistence of airway patency (pharma-
cologic “airway stenting”), associated with a more effective
prevention of COPD exacerbations, are likely to slow the
rate of disease progression, as well as to concomitantly re-
duce mortality.
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